
Cilosta100 mg
Square Pharmaceuticals PLC.
Cilostazol is FDA-approved for the reduction of symptoms of intermittent claudication, a condition caused by peripheral arterial disease (PAD) in which reduced blood flow to the legs causes pain and more.
Cilostazol is FDA-approved for the reduction of symptoms of intermittent claudication, a condition caused by peripheral arterial disease (PAD) in which reduced blood flow to the legs causes pain, cramping, or fatigue in the calf, thigh, or buttock muscles during walking or exercise.
Cilostazol does not cure peripheral arterial disease and does not replace lifestyle measures such as smoking cessation, supervised exercise programs, and control of cardiovascular risk factors.
| Population | Recommended Dose |
|---|---|
| Standard adult dose | 100 mg orally twice daily, taken at least 30 minutes before or 2 hours after breakfast and dinner |
| With strong CYP3A4 or CYP2C19 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, diltiazem, omeprazole, fluconazole) | Reduce dose to 50 mg twice daily (see Interactions) |
Clinical benefit typically becomes noticeable after 2-4 weeks of continuous therapy, but up to 12 weeks of treatment may be required for full effect. If no symptomatic improvement is observed after 3 months of therapy at the appropriate dose, continued treatment should be reassessed by a physician.
No dedicated dose adjustment is established for renal impairment based on standard labeling, but caution is advised in patients with significant renal disease; use should be guided by a physician.
Use with caution in patients with hepatic impairment, as Cilostazol is extensively metabolized by the liver; dosing should be individualized under medical supervision.
Safety and efficacy of Cilostazol in pediatric patients have not been established (see Use in Special Populations).
The most commonly reported adverse effects of Cilostazol (100 mg twice daily) include:
Other less common effects can include nausea, dyspepsia, peripheral edema, rhinitis, pharyngitis, and infection. Rare but serious effects can include significant bleeding (see Contraindications for bleeding-related risk factors) and hypersensitivity reactions. Patients should seek prompt medical attention for chest pain, irregular heartbeat, unusual bleeding or bruising, or signs of an allergic reaction (rash, swelling, difficulty breathing) while taking Cilostazol.
Cilostazol is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.